All Outputs (9)

Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study (2024)
Journal Article

Objectives Colchicine is commonly used to prevent flares when starting urate-lowering therapy for gout. Patients with gout are frequently concurrently prescribed other medications (such as statins) that may interact with colchicine, increasing the r... Read More about Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study.

Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink (2023)
Journal Article

Objectives: To determine the risk of adverse events associated with colchicine or non-steroidal anti-inflammatory drug (NSAID) prophylaxis when initiating allopurinol for gout. Methods: We conducted two matched retrospective cohort studies in... Read More about Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink.

P145 Safety of colchicine or NSAID prophylaxis when initiating allopurinol for gout: propensity score-matched cohort studies (2022)
Journal Article

Abstract Background/Aims Initiating urate-lowering therapy for gout commonly triggers a gout flare and hence co-prescription of colchicine or non-steroidal anti-inflammatory drug (NSAID) prophylaxis is recommended. However, little is known about the... Read More about P145 Safety of colchicine or NSAID prophylaxis when initiating allopurinol for gout: propensity score-matched cohort studies.

Mortality Among Patients With Polymyalgia Rheumatica: A Retrospective Cohort Study (2020)
Journal Article

OBJECTIVE: To determine whether a diagnosis of polymyalgia rheumatica (PMR) is associated with premature mortality. METHODS: We extracted anonymised electronic medical records of patients over the age of 40 years, who were eligible for linkage with t... Read More about Mortality Among Patients With Polymyalgia Rheumatica: A Retrospective Cohort Study.

Comorbidities in patients with polymyalgia rheumatica prior to and following diagnosis: A case control and cohort study (2020)
Journal Article

Objectives: To determine the burden of comorbidities, including glucocorticoid (GC) related adverse effects, in patients with polymyalgia rheumatica (PMR) before and after diagnosis. Methods: We extracted anonymised electronic medical records of p... Read More about Comorbidities in patients with polymyalgia rheumatica prior to and following diagnosis: A case control and cohort study.

Comorbidities in polymyalgia rheumatica: a systematic review (2018)
Journal Article

BACKGROUND AND AIM: Comorbidities are known to exist in many rheumatological conditions. Polymyalgia rheumatica (PMR) is a common inflammatory rheumatological condition affecting older people which, prior to effective treatment, causes severe disabil... Read More about Comorbidities in polymyalgia rheumatica: a systematic review.

Incidence, prevalence and treatment burden of Polymyalgia Rheumatica in the UK over two decades: a population-based study (2018)
Journal Article

Objective Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in older people. Contemporary estimates of the incidence and prevalence are lacking, and no previous study has assessed treatment patterns at a population level... Read More about Incidence, prevalence and treatment burden of Polymyalgia Rheumatica in the UK over two decades: a population-based study.

The real evidence for polymyalgia rheumatic as a paraneoplastic syndrome. (2018)
Journal Article

Not available.

The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome. (2018)
Journal Article

The aim of this study was to systematically consider the evidence for polymyalgia rheumatica (PMR) as a paraneoplastic disease. A systematic review of Medline and Embase was conducted from their inception to February 2017. Risk of bias was assessed u... Read More about The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome..